» Articles » PMID: 35217074

Evaluation of Anti-tumor Effect of the Exopolysaccharide from New Cold-adapted Yeast, Rhodotorula Mucilaginosa Sp. GUMS16 on Chronic Myeloid Leukemia K562 Cell Line

Overview
Publisher Elsevier
Date 2022 Feb 26
PMID 35217074
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, the development and application of fungal exopolysaccharides (EPS) as natural biopolymers are on the rise. The present study is based on the investigation of possible antiproliferative and antioxidant activities of EPS from the Rhodotorula mucilaginosa sp. GUMS16 on BCR-ABL positive cells (K562). The cytotoxicity, colony formation assays lactate and dehydrogenase (LDH) activity were performed to assess the possible cancer cell death. To elucidate the underlying antiproliferative mechanism of the EPS, cell cycle analysis following real-time PCR (gene expression assessment) were evaluated. The results indicated that, the EPS with an IC50 dose of 1500 μg/ml, reduced the viability of K562 cells without having toxic effects on normal cells as well as decrease in size and number of colonies in EPS-treated group (p < 0.0001). The increase of LDH was 2.75 times more than the control (p < 0.0001). Gene expression revealed up- and down-regulation of apoptotic and anti-apoptotic genes in EPS group compared with the control. Moreover, the DPPH scavenging activity of the EPS in treated cells was significantly higher than the control group (p < 0.0001). Taken together, we concluded that the EPS from GUMS16 strain is able to inhibit the growth of K562 cells besides having antioxidant activities.

Citing Articles

Astaxanthin Co-treatment with Low Dose Methotrexate Increases the Cell Cycle Arrest and Ameliorates the Methotrexate-induced Inflammatory Response in NALM-6.

Moridi N, Najafzadeh M, Sayedi M, Sajjadi S Int J Mol Cell Med. 2024; 13(2):133-146.

PMID: 39184820 PMC: 11344562. DOI: 10.22088/IJMCM.BUMS.13.2.133.


The impact of exosomes derived from B-cell acute lymphoblastic leukemia as a growth factor on bone marrow mesenchymal stromal cells.

Amirpour M, Kuhestani-Dehaghi B, Kheyrandish S, Hajipirloo L, Khaffafpour Z, Keshavarz F Mol Biol Rep. 2024; 51(1):749.

PMID: 38874800 DOI: 10.1007/s11033-024-09674-4.


Advancements in small interfering RNAs therapy for acute lymphoblastic leukemia: promising results and future perspectives.

Rastgar A, Kheyrandish S, Vahidi M, Heidari R, Ghorbani M Mol Biol Rep. 2024; 51(1):737.

PMID: 38874790 DOI: 10.1007/s11033-024-09650-y.


"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells".

Golestani A, Rahimi A, Najafzadeh M, Sayadi M, Sajjadi S Mol Biol Rep. 2024; 51(1):108.

PMID: 38227060 DOI: 10.1007/s11033-023-09135-4.


Glucose increases proliferation and chemoresistance in chronic myeloid leukemia via decreasing antioxidant Properties of ω-3 polyunsaturated fatty acids in the presence of Iron.

Shahraki S, Bahraini F, Mesbahzadeh B, Sayadi M, Sajjadi S Mol Biol Rep. 2023; 50(12):10315-10324.

PMID: 37971569 DOI: 10.1007/s11033-023-08891-7.